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INTRODUCTION 
Juvenile Idiopathic Arthritis (JIA) is defined as arthritis in one or 
more joints persisting for 6 weeks or more, which begins before the 16th 
birthday and has no other known cause.  
Enthesitis Related Arthritis (ERA) is a subtype that has replaced, 
but is not exactly overlapping with, previous definitions in children such 
as juvenile ankylosing spondylitis or syndrome of seronegative 
enthesitis arthritis. 
 ERA is defined as arthritis and enthesitis, or arthritis or enthesitis 
with at least two of the following: (1) sacroiliac joint tenderness, or 
inflammatory lumbosacral pain; (2) positive HLA-B27; (3) onset of 
arthritis in a boy 6 years old or older; (4) acute anterior symptomatic 
uveitis; or (5) history of ankylosing spondylitis, ERA, sacroiliitis with 
inflammatory bowel disease, Reiter's syndrome, or acute anterior uveitis 
in a first-degree relative.  
Exclusions include psoriasis in a first-degree relative, systemic 
features and a positive IgM RF on more than one occasion, 3 months 
apart. This form of JIA is more frequent in boys (male-to-female ratio of 
syndrome of seronegative enthesitis arthritis 7:1), although in some 
geographic areas it may be under recognized in symptomatic girls, who 
can have milder disease with less axial skeleton involvement.The onset 
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is typically in boys older than 6 years (commonly preteen or teenage) 
with peripheral arthritis affecting large joints, and there is a familial 
predilection. ERA is generally thought to be a form of 
spondyloarthropathy and has a strong association with HLA-B27. In 
patients who have the HLA-B27 gene, mechanisms may parallel those in 
adults with ankylosing spondylitis . There is overlap in terms of genetic 
factors and putative causative factors with reactive arthritis, although 
children with reactive arthritis are excluded from the ILAR criteria for 
JIA. 
A typical feature of ERA is the presence of enthesitis (i.e., 
inflammation of the insertion site of tendons, ligaments, fascia and 
capsule into the periosteum of bone). The typical sites are the inferior 
pole of the patella, Achilles' tendon, and plantar fascia insertions into 
the calcaneus. Not all entheses are equally significant in ERA, and some 
are prone to mechanical damage in other pediatric conditions, such as in 
Osgood-Schlatter disease. Metatarsalgia is common in children and 
should not count as enthesitis. The arthritis of ERA typically affects the 
hips, knees or ankles and may be symmetric or asymmetric. Joints are 
painful and stiff, sometimes with night pain. At onset, spinal symptoms 
are rare, but in a subgroup of children with ERA progress to features 
more typical of adult ankylosing spondylitis with sacroiliac joint and 
spinal inflammation. This progression is more likely in boys, who are 
HLA-B27 positive and have spinal or sacroiliac joint pain within 1 year 
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of diagnosis.ERA is associated with an acute anterior uveitis, which 
typically presents as an acutely red, painful eye and needs immediate 
medical attention because if untreated it may lead to blindness. 
In contrast to the western literature only 11-16% of patients with 
JIA have ERA, In India it is probably the commonest sub type of JIA 
seen clinically. Data on outcome of ERA patients from India are scarce. 
This study was taken up to assess the clinical profile and outcome of 
Juvenile idiopathic arthritis - enthesitis related arthritis. 
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REVIEW OF LITERATURE 
Juvenile idiopathic arthritis (JIA) is an umbrella term for 
childhood arthritis of unknown cause. 
JIA affects 1 in 1000 children. 
Many of the subtypes of JIA have particular features, but some 
complications are common to several subtypes. 
JIA is clearly distinct from adult rheumatoid arthritis. 
Progress in the understanding of the genetics and pathogenesis of 
JIA has revealed subtype-specific associations and some common 
mechanisms of disease. 
The principles of treating JIA are common to all subtypes because 
they involve a multidisciplinary approach, aiming to suppress 
inflammation early and maintain function. 
It has been more than a century since Still eloquently described 
the differences between forms of childhood arthritis and adult 
rheumatoid arthritis. Despite many advances in understanding of 
genetic, pathologic and molecular influences on the disease, the cause or 
causes of juvenile arthritis are unknown and it remains a leading cause 
of acquired disability in childhood. In more recent years, juvenile 
idiopathic arthritis has become widely accepted as an umbrella term to 
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cover this heterogeneous group of conditions. The classification of JIA, 
proposed and subsequently revised by the International League of 
Associations for Rheumatology (ILAR), has now replaced previous 
nomenclature, including the European term, juvenile chronic arthritis, 
and the American term, juvenile rheumatoid arthritis1,2. 
JIA is defined as arthritis in one or more joints persisting for 6 
weeks or more, which begins before the 16th birthday and has no other 
known cause. Each category has a list of possible inclusions and 
exclusions. A primary goal of such a system is to define mutually 
exclusive categories of idiopathic childhood arthritis based on 
predominant clinical and laboratory features, with the aim of improving 
therapy and management.  Although the classification of JIA is based 
primarily on clinical features of the disease, with emphasis on 
presenting features, it is widely accepted that improved knowledge 
should lead to a more precise definition of the types of JIA, perhaps 
based on genetic, pathologic, or mechanistic information, and that such 
a classification would need to evolve or change, as understanding of the 
subtypes of juvenile arthritis and their pathophysiology improves. The 
increasing use of one system of classification would facilitate ready 
comparison of data and information from many studies and clinical 
trials. 
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Many of the types of childhood arthritis have distinct clinical 
features, and some of these features are rare in adult inflammatory 
arthritis. In JIA, in contrast to adult rheumatoid arthritis, large joints, 
such as the knees, wrists and ankles are typically more prominently 
involved than small joints. Subcutaneous nodules and rheumatoid factor 
(RF) seropositivity are unusual, but antinuclear antibody (ANA) 
seropositivity is frequent in some JIA subtypes. Some JIA subtypes have 
a majority onset in young childhood, although as yet there is no clear 
biologic explanation for why this is so. Examples include the systemic-
onset and oligoarticular subtypes of JIA. In contrast, some JIA subtypes 
have an adult counterpart, such as psoriatic arthritis and RF-positive 
polyarticular JIA; these subtypes tend to have a slightly older onset in 
children. Some complications of JIA, such as osteoporosis or uveitis, 
can occur in many subtypes; others are more restricted to particular 
subtypes.  
ILAR 
Subtype 
Peak 
Age 
of 
Onse
t (yr) 
Female: 
Male; %
of All 
JIA 
Arthritis 
Pattern 
Extra-
articular 
Features
Investigation
s 
Notes on 
Therapy 
Systemic 
arthritis 
2-4 1:1; 
10% of 
JIA 
cases 
Polyarticular, 
often knees, 
wrists, and 
ankles; also 
fingers, neck, 
and hips 
Daily 
fever; 
evanescent 
rash; 
pericarditis
; pleuritis 
Anemia; WBC 
↑↑; ESR ↑↑; 
CRP ↑↑; 
ferritin ↑;  
platelets ↑↑ 
(normal or ↓ 
in MAS) 
Less 
responsive to 
standard 
treatment 
with MTX 
and anti-TNF 
agents; 
consider IL-
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ILAR 
Subtype 
Peak 
Age 
of 
Onse
t (yr) 
Female: 
Male; %
of All 
JIA 
Arthritis 
Pattern 
Extra-
articular 
Features
Investigation
s 
Notes on 
Therapy 
1Ra in 
resistant 
cases 
Oligoarthriti
s 
<6 4:1; 50-
60% of 
JIA (but 
ethnic 
variation
) 
Knees ++; 
ankles, 
fingers + 
Uveitis in 
30% 
ANA positive 
in 60%; other 
tests usually 
normal; may 
have mildly ↑ 
ESR/CRP 
NSAIDS and 
intra-articular 
steroids; 
occasionally 
require MTX
Polyarthritis
, RF 
negative 
6-7 3:1; 
30% of 
JIA 
cases 
Symmetric or 
asymmetric; 
small and 
large joints; 
cervical 
spine; TMJ 
Uveitis in 
10% 
ANA positive 
in 40%; RF 
negative;  
ESR ↑ or ↑↑;  
CRP ↑/ 
normal; mild 
anemia 
Standard 
therapy with 
MTX and 
NSAIDs, 
then if 
nonresponsiv
e, anti-TNF 
agents or 
other 
biologics 
Polyarthritis
, RF 
positive 
9-12 9:1; 
<10% of 
JIA 
cases 
Aggressive 
symmetric 
polyarthritis 
Rheumatoi
d nodules 
in 10%; 
low-grade 
fever 
RF positive;  
ESR ↑↑; CRP 
↑/ normal; 
mild anemia 
Long-term 
remission 
unlikely; 
early 
aggressive 
therapy is 
warranted 
Psoriatic 
arthritis 
7-10 2:1; 
<10% of 
JIA 
cases 
Asymmetric 
arthritis of 
small or 
medium 
sized joints 
Uveitis in 
10%; 
psoriasis in 
50% 
ANA positive 
in 50%; ESR 
↑;  
CRP 
↑/normal; 
mild anemia 
NSAIDS and 
intra-articular 
steroids; 
second-line 
agents less 
commonly 
Enthesitis-
related 
arthritis 
9-12 1:7; 
10% of 
JIA 
cases 
Predominantl
y lower limb 
joints 
affected; 
sometimes 
Acute 
anterior 
uveitis; 
association 
with 
80% HLA-
B27+ 
NSAIDS and 
intra-articular 
steroids; 
consider 
sulfasalazine 
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ILAR 
Subtype 
Peak 
Age 
of 
Onse
t (yr) 
Female: 
Male; %
of All 
JIA 
Arthritis 
Pattern 
Extra-
articular 
Features
Investigation
s 
Notes on 
Therapy 
axial 
skeleton (but 
less than 
adult AS) 
reactive 
arthritis 
and IBD 
as alternative 
to MTX 
(ANA, antinuclear antibody; AS, ankylosing spondylitis; CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate; IBD, 
inflammatory bowel disease; ILAR, International League of 
Associations for Rheumatology; IL-1Ra, interleukin-1 receptor 
antagonist; MAS, macrophage activation syndrome; MTX, methotrexate; 
NSAID, nonsteroidal anti-inflammatory drug; RF, rheumatoid factor; 
TMJ, temporomandibular joint; TNF, tumor necrosis factor; WBC, white 
blood cell count). 
Long-term studies have shown that, as a whole, JIA is not as 
benign as previously thought, with rates of complete remission off 
medication still low in many subtypes, evidence for loss of quality of 
life in childhood, and 30% to 50% of patients experiencing ongoing 
inflammation or disability into adulthood.  The imperative to investigate 
mechanisms of disease pathogenesis and search for new therapeutic 
avenues remains as strong as ever. A further drive to continue to aim for 
complete remission in JIA is the observation that when inflammation is 
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fully controlled, juvenile tissues, including synovium, cartilage, and 
bone, can undergo remarkable “healing” with restoration of function, in 
sharp contrast to adult arthritis. 
EPIDEMIOLOGY  
By definition, JIA begins before age 16 years. Young children 1 
to 3 years old are most commonly affected, a pattern most noticeable in 
girls, in whom the disease is twice as common. Boys have a wider 
distribution of age at onset, with a small peak in incidence at 8 to 10 
years. Systemic-onset JIA is an exception with a 1:1 female-to-male 
ratio. Studies of the incidence of childhood arthritis using either juvenile 
rheumatoid arthritis or juvenile chronic arthritis classifications have 
documented rates of 3.5 to 13.9 (confidence limits 9.9 to 18.8) per 
100,000 children/yr in population-based cohorts, and a population-based 
study using ILAR JIA criteria suggested a rate of 15/100,000 
children/yr.7,8 Prevalence of chronic arthritis in childhood has been 
estimated as 148/100,000 children in a Norwegian study, and 
400/100,000 children in a survey of 12-year-old schoolchildren.11 In the 
latter study, all children were examined by a pediatric rheumatologist, 
which may explain the higher prevalence estimate. Most quoted studies 
are from populations of northern European descent, but some reports 
suggest arthritis may be less common in Japanese, black and Asian 
children.13 
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GENETICS  
Despite significant advances in genetics and molecular 
immunology, understanding of the etiology of JIA is piecemeal. Genetic 
factors and environmental triggers are thought to play a part ultimately 
leading to abnormalities in the cellular, humoral, and innate arms of the 
immune system.18,19,20  The evidence for a genetic contribution to JIA 
comes from several sources. Twin studies show a high concordance of 
disease in monozygotic twins. A study of 164 affected sibling pairs with 
JIA showed a 70% concordance for gender, 73% for disease onset, and 
66% for disease course, considerably higher than in a non–affected 
sibling pair cohort.First-degree relatives of children with JIA have a 
higher rate of autoimmune disease than controls. Genetic influences on 
JIA susceptibility and phenotype are polygenic,and a more recent 
genome-wide scan in JIA affected sibling pair families has supported the 
idea that multiple genetic loci contribute to JIA susceptibility. 
The strong associations of specific alleles with JIA are within the 
major histocompatibility complex (MHC) system and were the first to be 
documented. Among the MHC class I loci, HLA-B27 is strongly 
associated with spondyloarthropathy, which in children is now termed 
enthesitis-related arthritis (ERA), whereas HLA-A∗0201 is increased in 
oligoarthritis.21,22,23 Multiple studies have revealed an increase in HLA-
DR alleles, of which the strongest are DRB1∗0801 and DRB1∗1101 
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with oligoarticular JIA and DRB1∗1301, in particular in ANA-positive 
cases.23  Several haplotypes across the MHC confer an increased risk for 
all types of JIA, such as DRB1∗08-DQA1∗0401-DQB1∗0402, which 
confers an odds ratio of 6.1 for persistent oligoarticular JIA and 10.3 for 
extended oligoarticular JIA. Frequency of the DRB1∗1301-DQA1∗01-
DQB1∗06 haplotype distinguishes persistent from extended 
oligoarticular JIA, whereas DRB1∗0801 and DRB1∗1401 are 
associated with polyarticular JIA. 
Together these effects may be large; in one study, the presence of 
the combination of the HLA-DRB1∗0801, HLA-DRB1∗1101, and 
HLA-DPB1∗0201 alleles conferred a relative risk. Some associations 
closely mirror the associations of the corresponding adult disease, such 
as the strong association of the HLA-B27 allele with ERA and the HLA-
DRB1∗0401 with RF-positive polyarticular JIA. Some of these 
allele/subtype associations show an age-specific effect, in that they 
confer risk over a specific age range only. Although systemic JIA shows 
weaker associations with HLA alleles, even in this subtype, specific 
haplotypes (e.g., DRB1∗11-DQA1∗05-DQB1∗03) are increased 
compared with control subjects. 
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Inflammatory cytokines have been an important target for drug 
development in JIA, and similarly their gene polymorphisms have been 
a key area of scrutiny. Several HLA-independent tumor necrosis factor 
(TNF) haplotypes are significantly associated with JIA, but the 
functional consequences of these alleles are unclear.Some of the best 
characterized non-HLA genetic associations in JIA have been 
established in systemic JIA. The hypothesis suggesting a link between 
systemic JIA and interleukin (IL)-6 was proposed in 1993,with many of 
the clinical features in systemic JIA resembling the phenotype of IL-6 
overexpression (e.g., fevers, stunted growth, anemia).A polymorphism (-
174G/C) in the regulatory region of the IL-6 gene alters transcription of 
IL-6 in response to IL-1 and lipopolysaccharide; patients with systemic 
JIA have significantly lower frequency of the protective CC 
genotype,and the IL-6 -174G allele was confirmed as a susceptibility 
gene for systemic JIA. 
More recent haplotype analysis of the IL-6 gene has confirmed a 
haplotype association with systemic JIA.A polymorphism in the 
promoter region of the macrophage inhibitory factor (MIF) gene is 
associated with JIA.This polymorphism (MIF -173∗C) results in higher 
MIF production in the serum and synovium of JIA patients and has been 
shown to be predictive of outcome of intra-articular steroid injections in 
systemic JIA. 
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The anti-inflammatory gene IL-10 was first studied in 
oligoarticular JIA. The “ATA” haplotype of three single nucleotide 
polymorphisms at the 5′ flanking end of the gene is associated with 
lower production of IL-10 by peripheral blood mononuclear cells, and 
was found more frequently in the more severe subtype of JIA, extended 
oligoarticular JIA, than the milder persistent oligoarticular JIA. IL-10 
and its family member IL-20 were found to be associated with systemic 
JIA. The gene PTPN22, a negative regulator of T cell responses, has 
been suggested to be associated with JIA also, but current evidence is 
conflicting.24,25   In contrast to studies using the candidate gene 
approach, future novel genetic associations will be elucidated through 
whole-genome scanning, requiring large multicenter case-control 
cohorts. 
ENVIRONMENT  
A study of socioeconomic factors in the etiology of JIA suggested 
that high parental income and being an only child may be associated 
with a higher risk of disease, and in a Finnish study of more than 58,000 
births, fetal exposure to smoking has been suggested to increase the risk 
of JIA in girls. The evidence that genetic risk alleles, such as those 
associated with HLA antigens, confer different risk of JIA across 
different ages, strongly suggests that crucial environmental triggers, 
which change with age, may be involved in the initiation of JIA. 
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Microbial triggers for JIA remain elusive. Borrelia burgdoferi, the 
infectious agent responsible for Lyme disease, Mycoplasma 
pneumoniae, and several viruses, such as rubella and parvovirus, can 
cause a clinical picture similar to JIA, leading to the hypothesis that JIA 
represents an immunologic response to an infectious trigger. Bacterial or 
viral DNA can be isolated from the joints or serum of JIA patients, but 
no single agent has been identified as a cause of JIA, and in most cases 
of JIA no persisting infectious agent can be shown.28 Epidemiologic 
studies searching for infectious “outbreaks” or seasonal variation in 
incident JIA cases, or in pregnant mothers whose children subsequently 
develop JIA, have provided conflicting results.  
An alternative role for microbial pathogens in the pathogenesis of 
JIA has been suggested through molecular mimicry. Heat shock proteins 
are proteins expressed by microbial and human cells in response to 
stress. Bacterial heat shock proteins are strong immunogens and may 
generate cross-reactive immune responses to self–heat shock proteins in 
humans. In oligoarticular JIA, reactivity to self–heat shock proteins 
correlates with disease remission,and synovial T cells generate a 
regulatory cell phenotype in response to self–heat shock protein 60, 
which was not detectable in the more severe polyarthritis subgroup. 
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PATHOGENESIS  
The pathologic hallmark of juvenile inflammatory arthritis is the 
inflamed synovium. Histology of this tissue shows thickened synovium 
that is highly vascular and shows marked hyperplasia of synoviocytes in 
the lining layer and a dense infiltrate of inflammatory cells, comprising 
T cells, macrophages and in some cases B cells and natural killer 
cells.31,32 The hypertrophied synovial layer is highly vascular, with 
endothelium expressing markers of activation such as HLA-DR and 
intracellular adhesion molecule 1. The vascularity is likely related to the 
increased production of proangiogenic factors, such as vascular 
endothelial growth factor and the angiogenic chemokines.  
Recruitment of this inflammatory infiltrate is likely mediated by 
multiple chemokines shown to be increased in JIA, including CCL3, 
CCL5, and CXCL10; IL-8; and monocyte chemotactic protein-1.37,38  
The strong association of many JIA subtypes with genetic variants 
at HLA loci, the central role of HLA class I and II proteins in T cell 
function, and the predominance of T cells in pathologic JIA synovial 
tissue and fluid led to intense investigation of the role of T cells in the 
pathology of JIA. T cells within the JIA joint are highly activated 
memory cells, expressing rapidly upregulated (CD69) and persistent 
(DR) activation markers. These T cells express a restricted set of T cell 
receptors: The clonotypes are large and long-lived, and the same 
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hierarchy of clones re-expands during a relapse or flare of disease.The 
finding that this oligoclonality in the intra-articular T cell population is 
more marked in CD4+ T cells in oligoarthritis (which is associated with 
class II HLA-DR genes), and yet more marked in CD8+ T cells in ERA 
(which is associated with the class I allele HLA-B27), supports the 
concept that recognition of MHC-peptide complexes by T cells plays a 
role in the pathogenesis of JIA. 
Early work on inflammatory cytokines produced by synovial T 
cells suggested that these were heavily skewed toward a T helper type 1 
(Th1) CCR5+CXCR3+ interferon-γ-producing lineage.46   More recent 
evidence suggests, however, that another proinflammatory T cell 
cytokine, IL-17, produced by Th17 cells, has an important role in JIA. 
Th17 cells are enriched in the joint in JIA, and their numbers are higher 
in children with the more severe extended oligoarticular JIA compared 
with children with milder, persistent oligoarticular disease. 
Many inflammatory cytokines and chemokines are abnormally 
increased in JIA and found at the site of destructive synovitis. Subtype 
differences have emerged, which may allow a “subtype-specific” 
profiling of serum or synovial fluid in the future, although such 
measurements have to take into account circadian rhythms and the short 
half-lives of these mediators.  Systemic JIA is associated with high 
levels of TNFα, IL-1, IL-6, MIF, and IL-18.50 In cases of classic 
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systemic JIA, the levels of IL-6 and IL-1 receptor antagonist increase 
and decrease in parallel with the fever and rash.IL-6 and MIF levels are 
each associated with disease activity in systemic JIA, and high synovial 
MIF levels predict poor response to intra-articular steroid injection.IL-1 
has been suggested to have a major role in the pathogenesis of systemic 
JIA,although results in this field are conflicting. 
In addition to the proinflammatory, destructive process within the 
joint, there is strong evidence for ongoing immunoregulation in JIA. The 
existence of a mild form of arthritis in which full-blown 
immunopathology can resolve and disease can enter full remission 
(known as persistent oligoarticular JIA) provides a unique model in 
autoimmunity: a mild self-remitting autoimmune pathology, which can 
be compared with more severe clinical subtypes. Children with 
persistent oligoarticular JIA have evidence of immunoregulation as 
shown by high numbers of CD25+ foxp3+ regulatory T cells in the joint, 
and these cells correlate with clinical phenotype and outcome. In 
addition, T cells specific for the conserved self-antigen heat shock 
proteins have been shown to be present at significantly higher numbers 
in children destined to have a mild disease course, and these self-antigen 
heat shock protein–specific cells are thought to play a regulatory role.  
The crucial role of dendritic cells in the control of this 
immunoregulation of JIA is a field of intense investigation.54 
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In addition to cells of the adaptive immune system, many other 
parts of the immune system are abnormally activated in JIA, including 
synovial macrophages, dendritic cells, and neutrophils.55  Modern high- 
methods of gene expression profiling and proteomics have shown 
differences between JIA clinical subtypes in several cell populations and 
between JIA patients before and after treatment and compared with 
controls. Ultimately, the understanding of pathologic mechanisms and 
alterations in the balance between immune activation and regulation, 
during disease and in response to treatment, should lead to a new set of 
molecular tools with which to separate clinical subtypes, predict disease 
course, and select tailored therapies for every child more accurately. 
CLINICAL FEATURES OF SUBTYPES OF JUVENILE 
IDIOPATHIC ARTHRITIS  
SYSTEMIC ARTHRITIS  
Systemic JIA is defined as arthritis associated with systemic 
features, typically quotidian spiking fevers of 39°C or greater for more 
than 2 weeks, accompanied by at least any one of the following: an 
evanescent rash, lymphadenopathy, serositis, or hepatosplenomegaly. 
This clinical subtype was previously known as Still's disease and has a 
recognized adult-equivalent condition, adult-onset Still's disease. 
Systemic JIA occurs in young children with a peak age in most series of 
2 to 4 years. The incidence is the same in both sexes in whites, in 
contrast to the other types of JIA. The prevalence of systemic JIA 
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approximates to 10 cases per 100,000, representing about 10% of JIA as 
a whole, although some surveys have suggested that it may be more 
frequent in Japan and India. 
There is only a weak association between the HLA region and 
systemic JIA in whites, but there is good evidence that genetic 
predisposition constitutes at least part of the cause of systemic JIA. 
Non-HLA genes, such as those coding for macrophage MIF, have been 
shown to be associated with JIA as a whole, and a variant of the IL-6 
gene confers susceptibility.  These genes are thought to predispose the 
patient to a vigorous inflammatory response to stimuli, such as 
infectious agents, and the net effect of the interaction between 
proinflammatory and anti-inflammatory proteins is probably the key to 
the clinical features in this subtype of JIA. IL-6 and IL-1 may play a 
role in the pathogenesis of systemic JIA and have been proposed as 
therapeutic targets. Several monocyte-derived and neutrophil-derived 
proinflammatory factors also are abnormal in systemic JIA, including 
the myeloid-related proteins S100A8 and S100A9, and neutrophil-
derived S100A12.Abnormalities of the adaptive immune system in 
systemic JIA may include a defect in perforin. Low levels are associated 
with severe disease, but can reverse when disease is controlled.  
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Clinical Manifestations  
The fever is typically spiking in character with a peak of at least 
39°C. It occurs once or twice a day and recurs each day (quotidian). 
This quotidian fever is accompanied by an evanescent salmon pink 
macular/urticarial rash, which can be itchy. The child is usually unwell 
and irritable during the fever, but often recovers in between. Other 
accompanying symptoms are headaches (sometimes with signs of 
meningism), arthralgia or arthritis, myalgia, abdominal pains from 
serositis that can mimic an acute abdomen, breathlessness and chest 
pains on lying flat indicating pericarditis, and acute chest pains from 
pleuritis. The severity of symptoms varies widely, ranging from fever 
and rash for 2 to 3 weeks followed by mild arthritis, to simultaneous 
onset of all the above-described symptoms. In the most severe cases, 
children also may present with features of secondary hemophagocytic 
lymphohistiocytosis (also known as macrophage activation syndrome), 
with signs of anemia, jaundice, and purpura in later stages.  
Laboratory Features  
There are no specific tests for systemic JIA, but there are 
characteristic patterns of laboratory abnormalities. There is typically a 
very high C-reactive protein and erythrocyte sedimentation rate, 
leukocytosis with neutrophilia, thrombocytosis and anemia, which may 
be profound. Liver enzymes, ferritin, and coagulation screen may be 
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abnormal in severe cases, and polyclonal hypergammaglobulinemia is 
frequent. There are no specific autoantibodies. 
OLIGOARTHRITIS  
Oligoarticular arthritis is the most common form of JIA and 
preferentially affects girls (female-to-male ratio of 4:1), with a peak 
onset before 6 years of age. It affects about 60 per 100,000 white 
children, but rates vary in different ethnic groups.Oligoarticular JIA 
affects four or fewer joints in the first 6 months of disease. If more than 
four joints become involved after 6 months, it is defined as extended 
oligoarthritis; otherwise, it is known as persistent oligoarthritis. There 
are several exclusion factors  including psoriasis in the patient or a first-
degree relative, systemic features, a positive IgM RF on more than one 
occasion 3 months apart, or a positive HLA-B27 test when in a boy in 
whom arthritis starts at 6 years or older. 
Clinical Manifestations  
Children with oligoarthritis present with involvement of one to 
four joints, most commonly the knees and ankles . Small joints of the 
hands are the third most commonly affected, but this pattern may 
portend the later onset of psoriatic arthritis. Temporomandibular joint 
arthritis is common, but is often detected late in the course of the 
disease because symptoms are uncommon. Initial wrist involvement is 
rare and may indicate progression to extended oligoarthritis, or 
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polyarticular disease. Shoulders are rarely involved. Cervical spine 
disease may be manifest by torticollis. Most children complain of pain, 
morning stiffness, and gelling, and a parent may notice a limp and joint 
swelling, or in a young child, a reluctance to walk and return to 
crawling. Twenty-five percent of cases seem to be painless, however, 
and only swelling is observed.  
The most common extra-articular manifestation is iridocyclitis, 
also known as chronic anterior uveitis. Twenty percent to 30% of 
children with oligoarticular JIA develop uveitis, which is generally 
asymptomatic. The eye is neither red nor photophobic. Uveitis is more 
prevalent in children who are ANA positive.62,63  All children with 
oligoarticular JIA should have a mandatory slit lamp examination of the 
eyes to rule out uveitis by an experienced ophthalmologist at 
presentation and every 3 to 4 months for the first year and then for 
several years, with recommended screening times depending on age at 
onset. Some physicians decrease the surveillance to every 6 months if 
the ANA is negative because a positive ANA test is a predictor of 
uveitis.64 
Laboratory Features  
Of children with oligoarthritis, 50% to 70% have a positive ANA 
test, typically 1:40 to 1:320 depending on the test system, and the rate is 
even higher in girls with an early onset. In some cases, a child has 
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mildly or moderately elevated acute-phase reactants, such as erythrocyte 
sedimentation rate or C-reactive protein, and in a few cases a mild 
anemia is present. A high erythrocyte sedimentation rate may predict 
progression to the extended subtype. Elevated acute-phase reactants may 
suggest other conditions, such as subclinical inflammatory bowel 
disease with associated arthropathy. 
POLYARTHRITIS, RHEUMATOID FACTOR NEGATIVE  
RF-negative polyarthritis is defined as arthritis affecting five or 
more joints in the first 6 months of disease, with a negative RF test. 
Patients who meet the criteria for systemic arthritis, ERA, and psoriatic 
arthritis are excluded. Extended oligoarthritis, another subgroup with a 
polyarticular course, is distinguished from RF-negative polyarthritis by 
having five or more affected joints after only 6 months of disease. There 
is a risk of misclassifying these two groups if a patient's presentation is 
delayed, or progression of arthritis occurs around the time point of 6 
months. 
RF-negative polyarthritis constitutes 20% to 30% of new 
cases.The British Paediatric Rheumatology National Diagnostic Register 
of 311 patients recorded a mean age of onset of 6.5 years for this 
subtype, with girls outnumbering boys by 3:1.Age-related analysis 
reveals a bimodal distribution of onset, however, with one peak around 
3.5 years and the other around 10 to 11 years. 
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Arthritis is usually insidious and can be symmetric or asymmetric, 
affecting large and small joints. The cervical spine and 
temporomandibular joint are often involved.  Some authors distinguish 
two clinical subgroups on the basis of ANA: (1) an ANA-positive group 
consisting of young girls (<6 years old) with an asymmetric-onset 
arthritis and at a high risk of uveitis, and (2) a slightly older group (7 to 
9 years old) of ANA-negative patients having symmetric involvement of 
large and small joints.Uveitis occurs in 5% to 20% of patients in the RF-
negative polyarthritis JIA subtype, generally patients with few affected 
joints. 
Laboratory Features  
Polyarthritis may be associated with elevated acute-phase 
reactants and mild anemia. The ANA test is positive in 40%, and the RF 
is negative by definition. 
POLYARTHRITIS, RHEUMATOID FACTOR POSITIVE  
RF-positive polyarticular JIA is defined as arthritis affecting five 
or more joints in the first 6 months of disease and a positive RF test on 
two occasions at least 3 months apart. RF-positive polyarthritis 
constitutes 5% to 10% of cases under the juvenile rheumatoid arthritis or 
juvenile chronic arthritis classifications.In the JIA classification, RF 
testing is crucial to avoid large numbers of children with polyarthritis 
being unclassifiable.RF-positive polyarthritis is more common in girls, 
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with reported female-to-male ratios of 5.7 to 12.8,  and can be 
considered as part of the spectrum of rheumatoid arthritis, sharing 
immunogenetic and serologic factors. HLA-DRB1∗0401 is strongly 
associated, and the HLA-DRB1∗0401 DQA1∗03 DQB1∗03 haplotype 
carries an increased odds ratio of 3.9 for this subtype, yet is protective 
for other subtypes of JIA. Anti–cyclic citrullinated peptide antibodies 
have been reported in 57% to 73% of this JIA subtype.  Disease 
expression differs from adults, perhaps because of the effects of 
environmental factors, the effects of arthritis on a growing body, and the 
psychosocial impact of chronic disease during adolescence, which is 
itself a period of significant change in an individual's independence and 
self-identity. 
Clinical Manifestations  
The arthritis is typically an aggressive, symmetric polyarthritis 
affecting the small joints of the hands, typically the proximal 
interphalangeal joints, metacarpophalangeal joints and wrists and with a 
large joint involvement in a pattern that resembles rheumatoid arthritis. 
Children frequently have more than 30 joints with arthritis. At onset, 
low-grade fever may be present, but it is distinctly different from 
systemic JIA. Felty's syndrome (splenomegaly and leukopenia) can 
occur in childhood RF-positive polyarthritis. Rheumatoid nodules occur 
in 10% of cases, most frequently around the elbow. Other extra-articular 
  26
manifestations are reported less often than in adults. Uveitis is an 
unusual feature of this subtype. 
Laboratory Features  
Polyarthritis may be associated with elevated acute-phase 
reactants and anemia (normocytic, normochromic). The ANA test is 
positive in a few cases, and the RF is by definition positive on two 
occasions 3 months apart. Similar to adult rheumatoid arthritis, RF 
testing typically detects IgM-anti-IgG. In these patients, anti–cyclic 
citrullinated peptide antibodies may be more specific and as in adults 
are associated with erosive arthritis. 
JIA- PSORIATIC ARTHRITIS 
It is defined as the combination of arthritis and psoriasis, or 
arthritis and at least two of the following: dactylitis, nail abnormalities 
(two or more nail pits, or onycholysis), or family history of psoriasis in 
a first-degree relative. The earlier proposed ILAR classification[ 
included second-degree relatives with psoriasis, but this was believed to 
classify too many cases incorrectly. A full family history is crucial, and 
without this children may be misclassified. 
Psoriatic JIA represents 2% to 15% of all JIA. In the United 
States, it is more common in whites than other racial groups; 
approximately 90% of patients are white. Girls are slightly more 
affected than boys, and the typical age of onset is 7 to 10 years, with 
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psoriasis typically occurring within 2 years of the onset of arthritis, 
although it can follow arthritis by many years. The specific etiology is 
unknown, but there is a strong genetic component with 40% of patients 
with psoriasis having an affected relative, and several candidate HLA 
and non-HLA genes have been identified .More recent data from adults 
have implicated the newly identified IL-17-secreting T cells (Th17) and 
related cytokine IL-22 in the pathogenesis of psoriasis. 
Clinical Manifestations  
Arthritis is typically asymmetric and can involve large joints 
(commonly knees and ankles) and small joints, classically dactylitis, 
more commonly in the feet than in the hands, and distal interphalangeal 
joints. The total number of joints generally is limited, and children 
frequently follow an oligoarticular course. Psoriatic JIA is associated 
with uveitis in 15% of children. These features are typical of 
oligoarthritis, and many children are first classified as having 
oligoarticular JIA before psoriasis is manifest in the child or relative. A 
more recent study of childhood psoriatic arthritis argued for two distinct 
subpopulations. The older group, median age 9.5 years were more likely 
to have oligoarthritis and had higher remission rates. Although many 
adults with psoriatic arthritis have features of a spondyloarthropathy, 
such as sacroiliitis or enthesitis, in the JIA classification these children 
are classified as having ERA, or, if they have psoriasis, are unclassified. 
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Laboratory Features  
Children with psoriatic arthritis may have mild elevation of the 
erythrocyte sedimentation rate, C-reactive protein, and platelets, and a 
mild anemia of chronic disease. The ANA test is positive in half of 
children with psoriatic arthritis. RF is negative by definition. 
UNCLASSIFIED JUVENILE IDIOPATHIC ARTHRITIS  
Because of the exclusion criteria within the ILAR classification, 
strict adherence to the ILAR system leads to some children being 
defined as unclassifiable ; this is distinct from the previous European 
League Against Rheumatism or American College of Rheumatology 
criteria for juvenile arthritis, which did not include an unclassified 
group. The unclassified cases are patients who are defined as not having 
fulfilled sufficient inclusion criteria for any category or are excluded by 
fulfilling criteria for more than one category. A child in the 
oligoarthritis subgroup would be excluded if he or she had a family 
history of psoriasis in a first-degree relative. Although this system 
caused considerable controversy when proposed, it is based on the 
premise that classification is primarily a research tool, and so the 
provision of an undifferentiated category would offer greater 
homogeneity for the remaining subgroups. 
For clinical purposes, treatment of such children follows the same 
guidelines as outlined earlier. Ultimately, the system for classifying JIA 
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reflects current understanding of the disease's pathophysiology. As this 
knowledge improves, future revisions would be increasingly useful in a 
clinical setting because patient categorization would offer accurate 
predictions of clinical response and prognosis. 
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REVIEW OF ENTHESITIS-RELATED ARTHRITIS 
ERA is a subtype that has replaced, but is not exactly overlapping 
with, previous definitions in children such as juvenile ankylosing 
spondylitis or syndrome of seronegative enthesitis arthritis. ERA is 
defined as arthritis and enthesitis, or arthritis or enthesitis with at least 
two of the following: (1) sacroiliac joint tenderness, or inflammatory 
lumbosacral pain; (2) positive HLA-B27; (3) onset of arthritis in a boy 6 
years old or older; (4) acute anterior symptomatic uveitis; or (5) history 
of ankylosing spondylitis, ERA, sacroiliitis with inflammatory bowel 
disease, Reiter's syndrome, or acute anterior uveitis in a first-degree 
relative. Exclusions include psoriasis in a first-degree relative, systemic 
features and a positive IgM RF on more than one occasion 3 months 
apart. 
This form of JIA is more frequent in boys (male-to-female ratio of 
syndrome of seronegative enthesitis arthritis 7:1), although in some 
geographic areas it may be underrecognized in symptomatic girls, who 
can have milder disease with less axial skeleton involvement.The onset 
is typically in boys older than 6 years (commonly preteen or teenage) 
with peripheral arthritis affecting large joints, and there is a familial 
predilection. ERA is generally thought to be a form of 
spondyloarthropathy and has a strong association with HLA-B27. In 
patients who have the HLA-B27 gene, mechanisms may parallel those in 
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adults with ankylosing spondylitis . There is overlap in terms of genetic 
factors and putative causative factors with reactive arthritis, although 
children with reactive arthritis are excluded from the ILAR criteria for 
JIA. 
CLINICAL MANIFESTATIONS  
A typical feature of ERA is the presence of enthesitis. The typical 
sites are the inferior pole of the patella, Achilles' tendon, and plantar 
fascia insertions into the calcaneus. Not all entheses are equally 
significant in ERA, and some are prone to mechanical damage in other 
pediatric conditions, such as in Osgood-Schlatter disease. Metatarsalgia 
is common in children and should not count as enthesitis. The arthritis 
of ERA typically affects the hips, knees, or ankles, and may be 
symmetric or asymmetric. Joints are painful and stiff, sometimes with 
night pain. At onset, spinal symptoms are rare, but in a subgroup of 
children with ERA progress to features more typical of adult ankylosing 
spondylitis with sacroiliac joint and spinal inflammation. This 
progression is more likely in boys, who are HLA-B27 positive and have 
spinal or sacroiliac joint pain within 1 year of diagnosis.ERA is 
associated with an acute anterior uveitis, which typically presents as an 
acutely red, painful eye and needs immediate medical attention because 
if untreated it may lead to blindness . 
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LABORATORY FEATURES  
There is no diagnostic laboratory test, although HLA-B27 is 
present in 80% to 90% of cases and helps establish this diagnosis. The 
erythrocyte sedimentation rate may be mildly or markedly increased, 
and there may be a mild anemia, but these also should raise the 
suspicion that the patient may have subclinical inflammatory bowel 
disease. RF is negative by definition; ANA may be positive.64 
Ultrasound can distinguish enthesitis even in asymptomatic individuals. 
HUMAN LEUKOCYTE ANTIGEN (HLA) B27   
It is a class I surface antigen encoded by the B locus in the major 
histocompatibility complex (MHC) on chromosome 6 and presents 
antigenic peptides (derived from self and non-self antigens) to T-cells. 
HLA-B27 is strongly associated with ankylosing spondylitis (AS), and 
other associated inflammatory diseases referred to collectively as 
"spondyloarthritis". The prevalence of HLA-B27 varies markedly in the 
general population. For example, about 8% Caucasian, 4% North 
Africans, 2-9% Chinese, and 0.1-0.5% Japanese possess this gene. In 
Northern Scandinavia (Lapland), 24% of people are HLA-B27 positive, 
while 1.8% have associated ankylosing spondylitis (AS). Examining 
HLA types. 
SEROTYPE AND ALLELE NAMES 
There are two parallel systems of nomenclature that are applied to 
HLA. The, first, and oldest system is based on serological (antibody 
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based) recognition. In this system antigens were eventually assigned 
letters and numbers (e.g. HLA-B27 or, shortened, B27). A parallel 
system was developed that allowed more refined definition of alleles, in 
this system a "HLA" is used in conjunction with a letter * and four or 
more digit number (e.g. HLA-B*0801, A*68011, A*240201N N=Null) 
to designate a specific allele at a given HLA locus. HLA loci can be 
further classified into MHC class I and MHC class II (or rarely, D 
locus). Every two years a nomenclature is put forth to aid researchers in 
interpreting serotypes to alleles. 
SEROTYPING 
In order to create a typing reagent, blood from animals or humans 
would be taken, the blood cells allowed to separate from the serum, and 
the serum diluted to its optimal sensitivity and used to type cells from 
other individuals or animals. Thus serotyping became a way of crudely 
identifying HLA receptors and receptor isoforms. Over the years 
serotyping antibodies became more refined as techniques for increasing 
sensitivity improved and new serotyping antibodies continue to appear. 
One of the goals of serotype analysis is to fill gaps in the analysis. It is 
possible to predict based on 'square root' 'maximum-likelihood' method, 
or analysis of familial haplotypes to account for adequately typed 
alleles. These studies using serotyping techniques frequently revealed, 
particularly for non-European or north East Asian populations a large 
number of null or blank serotypes. This was particularly problematic for 
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the Cw locus until recently, and almost half of the Cw serotypes went 
untyped in the 1991 survey of the human population. 
There are several types of serotypes. A broad antigen serotype is a 
crude measure of identity of cells. For example HLA A9 serotype 
recognizes cells of A23 and A24 bearing individuals, it may also 
recognize cells that A23 and A24 miss because of small variations. A23 
and A24 are split antigens, but antibodies specific to either are typically 
used more often than antibodies to broad antigens. 
DIFFERENTIAL DIAGNOSIS  
Some children with prolonged reactive arthritis, or arthritis 
associated with inflammatory bowel disease, have enthesitis and would 
be classified as having ERA if the infective agent were not identified, or 
until inflammatory bowel disease is diagnosed. Other conditions that 
may mimic ERA include reactive arthritis in children and pain 
syndromes; children with widespread amplified musculoskeletal pain 
may have very tender entheses that can be mistaken for enthesitis. 
TREATMENT  
Treatment of ERA is similar to that for oligoarthritis and 
polyarthritis.66,67  Most patients respond to intra-articular corticosteroid 
injections, but many need a disease-modifying antirheumatic drug and 
respond well to sulfasalazine or methotrexate, although there has been 
no comparison of the two agents in children.68,69  If disease is severe, a 
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course of intravenous pulse methylprednisolone is often helpful. 
Children with enthesitis require an NSAID for symptomatic relief. Many 
physicians empirically favor certain NSAIDs for enthesitis, specifically 
diclofenac and indomethacin. Occasionally, corticosteroid injection of 
the plantar fascial insertion on the calcaneus is helpful. Physical therapy 
is central to management (as for all JIA), and orthotics and shoe 
modification can help greatly. These measures have not proved to 
modify the course of disease significantly, in particular, axial and spinal 
inflammation. 
In open label studies, the anti-TNF-α agents infliximab and 
etanercept have been shown to be effective agents for axial disease.73,74  
Anti-TNF-α agents should be used early in the course of axial disease, 
before irreversible damage from spinal erosion and fusion occurs. Anti-
TNF-α agents also are associated with improvement in peripheral 
arthritis and enthesitis.  
 The modern treatment of JIA involves a range of specialists. 
Early use of combination of disease-modifying agents can suppress 
disease activity in many cases. Pediatric rheumatologists have in their 
favor the remarkable capacity for childhood growth and development to 
allow repair and restoration of function, in contrast to adults with 
inflammatory arthritis.  
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A persistent block to good outcome in many areas of the world is 
a delay in recognition, late referral and diagnosis of JIA.  
When JIA is recognized, children who receive active treatment 
through a multidisciplinary approach should have an improving 
prognosis in the years to come. The advent of new biologic therapies 
and rapid translation of basic research into therapeutic strategies and an 
increased willingness on the part of regulatory bodies to make new 
therapies available to children should combine to continue to improve 
the outlook for children with arthritis. 
 Thus the long-term outcome of ERA is unknown, but a proportion 
of these children progress to the adult form of ankylosing spondylitis. 
Enthesitis can be more symptomatic in teens and young adults and 
improves with age. Spinal and sacroiliac joint involvement in teenagers, 
if left untreated, can lead to ankylosis, as in adults. Boys with HLA-B27 
and hip arthritis are at higher risk of developing progressive spinal 
involvement. 
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AIM 
The aim of the study is 
1) To study the clinical profile and outcome of Juvenile idiopathic 
arthritis -enthesitis related arthritis. 
2) To study the incidence of Juvenile ankylosing spondylitis. 
3) To study the association of HLA_B27 and sacro iliac joint 
involvement. 
  38
MATERIALS AND METHODS 
The study period was from January 2009 to March 2011. History, 
clinical examination, radiological imaging like musculoskeletal X-rays, 
musculoskeletal USG and CT of sacroiliac joints, biochemical 
investigations and immunological investigations were done for all 
patients.  
Material and Selection: Inpatients and outpatients of Department 
of Rheumatology, Rajiv Gandhi Govt. General Hospital and Madras 
Medical College, Chennai. The study was under taken after obtaining 
approval from the institutional ethical committee. An informed consent 
was obtained from all patients and parents. 
The study period was from January 2009 to March 2011. 
Sample size: 50 
Study design: Cross sectional study 
Inclusion criteria are [1]: onset of arthritis before the 16th 
birthday and persisting for at least 6 weeks; arthritis and enthesitis, or 
arthritis or enthesitis with at least 2 of 
a) Presence of or a history of sacroiliac joint tenderness and/or 
inflammatory lumbosacral pain, 
b) Presence of HLA-B27 antigen, 
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c) Onset of arthritis in a male over 6 years of age. 
d) Acute (symptomatic) anterior uveitis 
e) History of ankylosing spondylitis, enthesitis related arthritis, 
sacroiliitis with inflammatory bowel disease, Reiter's syndrome, or 
acute anterior uveitis in a first-degree relative. 
 By definition, patients with psoriasis or a history of psoriasis in 
the patient or first-degree relative, presence of IgM rheumatoid factor 
and systemic JIA are not included in ERA subtype. 
 JADI (Juvenile articular demage index) scores were calculated as 
described previously. The index is composed of articular (JADI-A) and 
extraarticular (JADI-E) damage. In the JADI-A, 36 joints or joint groups 
are assessed for the presence of damage: cervical spine, shoulders, 
elbows, wrists, individual metcarpophalangeal and proximal 
interphalangeal joints, hips, and knees; right and left temporomandibular 
joints, ankle and subtalar joints and metatarsophalangeal joint of each 
foot are considered as a single unit. The damage observed in each joint 
is scored as 1 in case of partial damage, or 2 in case of severe damage, 
ankylosis, or prosthesis. Contractures and other joint deformities are 
scored when they are completely explained by prior damage and are not 
due to active arthritis and are present for at least 6 months. For each 
joint, only the most severe lesions are scored. The maximum possible 
JADI-A score is 72. 
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For JADI-E, muscle atrophy, osteoporosis with fractures or 
vertebral collapse, avascular necrosis of bone, significant abnormality of 
the vertebral curve due to leg length discrepancy or hip contracture, 
significant leg length discrepancy or growth abnormality of a bone 
segment, striae rubrae, subcutaneous atrophy resulting from 
intraarticular corticosteroid injection, growth failure, pubertal delay, 
diabetes mellitus and amyloidosis are scored as 1 if present; ocular 
complications like cataract or other complications of uveitis were scored 
as 1 if present, 2 if surgery was required and 3 in case of blindness. 
Abdominal fat pad analysis for amyloidosis was done if there was 
edema, hypertension, anasarca, proteinuria or disproportionately 
increased ESR. Growth was assessed by plotting height and weight on 
standardized Indian pediatric growth charts. Growth failure was defined 
as the presence of two or more of the following: less then 3rd percentile 
height for age, growth velocity less than 3rd percentile for age or 
crossing at least 2 percentile on growth chart. Delayed puberty was 
defined if no testicular enlargement occurred by 14 years of age. 
Educational level achieved, loss of school years, functional status 
measured by HAQ-S were also recorded. For the purposes of analysis, 
the HAQ-S score was divided into 4 categories: 0 = no disability, >0 and 
≤ 0.5 = mild disability, >0.5 and ≤1.5 = moderate disability, and > 1.5 = 
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severe disability . Hundred mm Visual Analogue Scale (VAS) was used 
for parent/patient's assessment of their disease. 
Examination included physician's global assessment on 100 mm 
VAS, number of active joints as defined by presence of swelling 
(excluding bony swelling) or any two of limitation of motion (LOM), 
pain, heat, or tenderness and number of joints with limited range of 
motion (ROM); 67 joints were assessed . 
Enthesitis was defined as discretely localized tenderness at the 
point of insertion of ligaments, tendons, joint capsules, or fascia to 
bone. Anterior lumbar flexion was assessed using the modified 
Schober's method. Reduced lumbar flexion was defined as values ≤ 6.5 
cm in boys and ≤ 5.5 cm in girls. Inflammatory back pain was defined as 
lumbosacral spinal pain at rest, with morning stiffness that improved 
with movement. Erythrocyte Sedimentation rate (ESR) was measured by 
Westergren method.  
ENTHESITIS 
Enthesitis is inflammation of the entheses, the sites where tendons 
or ligaments insert into the bone. It is also called enthesopathy or any 
pathologic condition involving the entheses. The entheses are any point 
of attachment of skeletal muscles to the bone, where recurring stress or 
inflammatory autoimmune disease can cause inflammation or 
occasionally fibrosis and calcification. One of the primary entheses 
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involved in inflammatory autoimmune disease is at the heel, particularly 
the Achilles tendon. 
It is associated with HLA B27 arthropathies like ankylosing 
spondylitis, psoriatic arthritis, and reactive arthritis (Reiter's syndrome).  
Symptoms include multiple points of tenderness at the heel, tibial 
tuberosity, iliac crest, and other tendon insertion sites.The entheses of 
the lower limbs are more frequently involved than those of the upper 
limbs, and heel enthesitis is the most frequent. Entheseal pain may be 
mild or moderate as well as severe and disabling. Peripheral enthesitis 
may be observed in all forms of spondyloarthritis, including the 
undifferentiated forms, and may, for a prolonged period, be the only 
longstanding clinical manifestation of the B27-associated disease 
process. The conceptual understanding of spondyloarthritis and the 
ability to image sites of skeletal inflammation accurately, i.e. ultrasound 
and magnetic resonance imaging, confirm that enthesitis is the primary 
lesion of spondyloarthritis. This advance has been occurring 
simultaneously with the therapeutic advances in spondyloarthritis due to 
the introduction of anti-tumour necrosis factor-alpha agents. 
Patients with features of enthesitis were subjected to under gone 
Musculoskeletal Ultra Sound of affected entheses. Ultrasound was done 
by a radiologist who was trained in musculoskeletal imaging. The 
frequency of Ultra Sound probe was 10.5 MHz. 
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X RAY SACROILIAC JOINT 
Conventional x-ray still remains as the imaging method most 
utilized in the clinical practice. An international consensus still remains 
to be reached regarding the best technique and view for radiographic 
evaluation of the sacroiliac joint. A Ferguson's view is taken at 30 
degrees cephalic to the pelvis and will show sacroiliitis much better than 
the regular AP pelvis. If further imaging is desired after normal X-rays, 
a CT scan is more sensitive than an MRI or bone scan. If there is some 
doubt regarding the diagnosis, one can repeat X-rays of the pelvis in 6 
months and compare the sacroiliac joints.. Anteroposterior views with 
25–30º caudal angulation of the x-ray tube, and oblique views are the 
most utilized in our practice, in an attempt to minimize structures 
overlapping, so facilitating the study interpretation. 
The main limitation of the x-ray film is the low sensitivity for 
detecting abnormalities in the early stages of the disease. Radiographic 
signs in sacroiliitis appear only three to seven years after the initial 
symptoms onset, presenting with alterations only in the chronic phase of 
the disease. 
The main radiographic signs are: bone erosions, joint space 
alterations, subchondral sclerosis and ankylosis. 
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CT SACROILIAC JOINT  
Imaging methods like CT and MRI are extremely useful, 
especially in the absence of alterations, or when they are minimal on 
plain x-ray. 
The evaluation of sacroiliitis by CT, in comparison with the 
conventional x-ray, has shown to be more sensitive, with a better and 
earlier detection of bone alterations, principally because of its capability 
to perform sequential slices, so avoiding structures overlapping. 
The CT shows higher sensitivity for detecting minimal bone 
erosions and joint space narrowing, however presents the same 
diagnostic capacity of plain x-rays in cases of ankylosis.  
The most frequent findings of sacroiliitis on CT are: joint space 
narrowing, subchondral sclerosis, bone erosions and ankylosis. Joint 
space narrowing is characterized by a thickness of less than 2.0 mm in 
synovial tissues. Subchondral sclerosis is found in the presence of an 
asymmetrical or focal area with increased density (> 5.0 mm on the iliac 
side, and > 3.0 mm on the sacral side). Bone erosions are small cortical 
defects on the synovial portion of the joint. These two latter findings 
can be seen in both sides of the joint, however, they are frequently seen 
at the iliac side because this side presents lower thickness and some 
cartilaginous clefts. The focal or complete fusion of the joint 
characterizes ankylosis observed in more advanced stages of the disease. 
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Alterations in the ligamentous portion are rare, when compared 
with the synovial portions. CT is better than MRI for detecting bone 
formation in the enthesis of this topography. 
CT is comparable to MRI for detecting bone erosion, but is 
superior for evaluating bone sclerosis and ankylosis, and is indicated 
especially for detecting chronic alterations. 
CT is a method of excellence in demonstrating bone details, 
besides serving as a guidance tool in percutaneous biopsies, 
arthrocentesis, and for intra-articular injection of steroids. 
On the other hand, sacroiliac evaluations by CT presents some 
inconveniences like radiation exposure, and incapacity to show 
alterations in the acute phase, identifying especially the inflammation 
consequences rather than the inflammatory process activity. 
SACROILIAC JOINT 
The SIJ is a true diarthrodial joint that joins the sacrum to the 
pelvis. In this joint, hyaline cartilage on the sacral side moves against 
fibrocartilage on the iliac side. The joint is generally C shaped with 2 
lever arms that interlock at the second sacral level. The joint contains 
numerous ridges and depressions, indicating its function for stability 
more than motion. 
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The sacroiliac (SI) joint has several unique anatomical features 
that make it one of the more challenging joints to image. The joint is 
difficult to profile well on radiographic views, and therefore the 
radiographic findings of sacroiliitis are often equivocal. Computed 
tomography images can usually show the findings of sacroiliitis earlier 
than radiographs. Magnetic resonance imaging performed with proper 
sequences is excellent for diagnosing even very early sacroiliitis and for 
following treatment response. Ankylosing spondylitis often presents 
with sacroiliitis, which appears as erosions, sclerosis, and joint space 
narrowing, eventually leading to ankylosis. 
HLA B 27 TEST BY FLOWCYTOMETRY 
For the flow cytometric assay, whole blood was mixed with a 
monoclonal anti-B27 conjugated to fluorescein-isothiocyanate (FITC) 
and anti-CD3 conjugated to phycoerythrin (PE). The samples were 
analyzed with flow cytometry by gating on CD3 positive events and 
anti-B27 staining intensity was evaluated as median channel 
fluorescence of the histogram peak.  For greatest specificity, samples 
positive by flow cytometry should be confirmed by conventional 
microlymphocytotoxicity or by use of other monoclonal antibodies 
directed against B27. 
STATISTICAL ANALYSIS 
Statistical analysis was performed using the SPSS version 17.0 
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RESULTS 
The median age at the time of the study of the 50 patients with ERA was 
16 years (range 9–33 years) and the median duration of disease was 5 years (3 
months–18 years). 49patients were male and one patient was female. Median 
age at disease onset was 14 (8–15) years. 17(34%) of the patients were HLA B 
27 positive. Three (6%) patients were in remission at the time of the study. 15 
patients (30%) had joints with limitation of motion. 18 (36%) patients had 
decreased anterior lumbar flexion movement by modified Schober's method.  
Table 1- Frequency of number of joints with limited range of 
motion (LOM) 
Number of joints with LOM Frequency (N = 50) Percentage
0 35 70 
1 1 2 
2 6 12 
3 2 4 
4 2 4 
5 4 8 
At the time of the study, all patients were on NSAID; 
Indomethacin was the most commonly prescribed NSAID. 40patients 
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(80%) were on it. 21 patients (42%) had received intra-articular (IA) 
steroid. All patients were on DMARDs at the time of the study. 
Sulphasalazine  was the commonest DMARD used (n = 36, 64%).14 
(28%) patients were on Methotrexate. Side effects of drug were seen in 
7 patients.  GI toxicity in 8 patients. 
JADI-A 
In JADI-A scoring 15 patients (30%) had damaged joints. JADI-A 
score varied from 1 – 6. Hip was the commonest damaged joint (n = 7; 
14%), followed by knees (3, 6%), ankle (3, 6%), elbows (2, 4%). The 
frequency distribution of JADI-A score are shown in table 2.  
Table 2 - Frequency of juvenile arthritis damage index-articular 
(JADI-A)-score 
JADI Score Frequency (N = 50) Percent 
0 35 70 
2 2 4 
3 4 8 
4 5 10 
5 2 4 
6 2 4 
  49
JADI-E 
2 (4%) patients had extraarticular damage with JADI-E.  None of 
the patients had ocular damage, severe muscular atrophy, growth failure, 
pubertal delay and Secondary amyloidosis. 
ENTHESITIS 
Ultrasound detect enthesitis in two asyptomatic individuals. 
Table - 3: Active enthesitis was present in 70% of the patients. 
Type of enthesitis Frequency (N = 35) Percentage 
Achillis enthesitis 21 58.4 
Plantar fascitis 12 33.6 
Knee enthesitis 6 16.8 
Spine enthesitis 1 2.8 
Elbow enthesitis 1 2.8 
Polyenthesitis were present in 11 patients. 
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DISEASE ACTIVITY 
Parent's/patient's global assessment on visual analogue scale 
(VAS) ranged from 0–100 mm .Median score of physician's global 
assessment in VAS was 30 mm (range 10–90 mm).  Number of active 
joints varied from 1–12(median 2.0). Duration of EMS ranged from nil 
to 1 hour and Median ESR was 40 (5–124) mm/hour. 
DISABILITY 
 Mild disability in 11(22%) patient.  Median HAQ-S was 1.0 (1–3). 
4 (8%) patients lost some years of education due to disease 
ranging from 2–10 years. 
HAQ-S had correlation with limitation of spinal mobility by 
modified Schober's method. 
HLA B27 
HLA B27 was positive in 17 (34%) patients, 16 (35%) were male 
and 1 (2%) was female.  
SACROILIAC JOINT INVOLVEMENT 
18 (36%) patients had sacroiliac joint involvement in both clinical 
and in radiological investigations. Among these patients 12 (24%) 
patients were HLA B27 positive and 6 (12%) patients were HLA B27 
negative. 
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DISCUSSION 
Our study shows 70% of patients had enthesitis, compare to 60% 
of patients had enthesitis in Sarma.P, Misra.R, Amita Agarwal.A et al., 
Lucknow study89.  Presence of enthesitis had a highly significant 
correlation with HAQ-S in our study. 
15 ERA patients had articular damage and 2 patients had 
extraarticular damage at a median duration of disease of 5years. 
Moderate limitation of movement of lumbar spine was present in 
18(36%) patients.  5 (10%) patients continued to have active disease. 
4(8%) patients lost some years of education due to disease ranging from 
2–10 years. 
More than 60% of patients lost some years of education in 
Lucknow study. Only 3% of patients were behind age appropriate grade 
in a study from Canada89. Education level attainment of adults with JIA 
was similar to controls in 2 studies from UK and Finland89.  
15 patients had damaged joints in JADI-A. Hip was the 
commonest joint damaged in our study followed by knees, ankles and 
elbow. In Lucknow study hip, knees, ankle  and cervical spine were 
more often involved.  JADI-A score in our study is lower compared to 
the Lucknow study.89 
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Sulphasalazine was the commonest DMARD used in our study,in 
contrast to Lucknow study in which methotrexate  was the commonest 
DMARD.89 
The limitation of application of JADI in ERA is absence of 
scoring for spinal involvement. Limitation of spinal mobility had high 
correlation with HAQ-S. Inclusion of limitation of spinal movement in 
JADI may be helpful to detect early damage in ERA.  
In our study 18 (36%) patients had decreased anterior lumbar 
flexion movement by modified Schober's method. In Lucknow study 
among the 49 patients, One third had limitation of lumbar spine 
movement by modified Schober's method.89 
HLA B27 
HLA B27 was positive in 17 (34%) patients, 16 (35%) were male 
and 1 (2%) was female.  
SACROILIAC JOINT INVOLVEMENT 
18 (36%) patients had sacroiliac joint involvement in both clinical 
and in radiological investigations. Among these patients 12 (24%) 
patients were HLA B27 positive and 6 (12%) patients were HLA B27 
negative. 
In our study  none of the patients had severe muscular atrophy, 
growth failure, pubertal delay ,in contrast to Lucknow study in which 
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three patients (6.1%) had severe muscular atrophy, pubertal delay was 
seen in 2 (4.1%)  and  Secondary amyloidosis was seen in 1 (2.0%). 
None of the patients had ocular damage in our study similar to Lucknow 
study. 
Our study has many limitations: numbers of patients are small, is 
a cross sectional study, the average disease duration is only 5 years. 
  54
CONCLUSION 
1) Axial inflammation was common in HLA-B27 positive patients. 
2) Functional limitations was observed in one third of the Enthesitis 
Related Arthritis patients. 
3) JADI is a useful tool to measure articular and extraarticular 
damage in ERA. 
4) 70% of JIA-ERA patients had enthesitis (Two third of patients 
had enthesitis). 
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APPENDICES 
International League of Associations for Rheumatology 
Classification of Juvenile Idiopathic Arthritis (JIA) 
Category Definition Exclusions 
Systemic onset 
JIA 
Arthritis in ≥1 joints with, 
or preceded by, fever of at 
least 2 wk duration that is 
documented to be daily 
(“quotidian”[∗]) for at 
least 3 days and 
accompanied by ≥1 of the 
following:
A. Psoriasis or a history 
of psoriasis in the patient 
or a first-degree relative 
 1. Evanescent (nonfixed) 
erythematous rash 
B. Arthritis in an HLA-
B27+ male beginning 
after the 6th birthday
 2. Generalized lymph 
node enlargement 
C. Ankylosing 
spondylitis, enthesitis-
related arthritis, 
sacroiliitis with 
inflammatory bowel 
disease, Reiter's 
syndrome, or acute 
anterior uveitis, or a 
history of one of these 
disorders in a first-
degree relative 
 3. Hepatomegaly or 
splenomegaly or both 
D. Presence of IgM RF 
on at least 2 occasions at 
least 3 mo apart 
 4. Serositis[†]  
Oligoarticular 
JIA 
Arthritis affecting 1-4 
joints during the first 6 
mo of disease. Two 
subcategories are 
recognized:
A, B, C, D above, plus 
Oligoarticular 
JIA 
Arthritis affecting 1-4 
joints during the first 6 
mo of disease. Two 
subcategories are 
recognized:
A, B, C, D above, plus 
 1. Persistent 
oligoarthritis—affecting 
E. Presence of systemic 
JIA in the patient 
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Category Definition Exclusions 
≤4 joints throughout the 
disease course
 2. Extended 
oligoarthritis—affecting 
>4 joints after the first 6 
mo of disease
 
 1. Persistent 
oligoarthritis—affecting 
≤4 joints throughout the 
disease course
E. Presence of systemic 
JIA in the patient 
 2. Extended 
oligoarthritis—affecting 
>4 joints after the first 6 
mo of disease
 
Polyarthritis (RF 
negative) 
Arthritis affecting ≥5 
joints during the first 6 
mo of disease; a test for 
RF is negative
A, B, C, D, E 
Polyarthritis (RF 
positive) 
Arthritis affecting ≥5 
joints during the first 6 
mo of disease; ≥2 tests for 
RF at least 3 mo apart 
during the first 6 mo of 
disease are positive
A, B, C, E 
Psoriatic 
arthritis 
Arthritis and psoriasis, or 
arthritis and at least 2 of 
the following:
B, C, D, E 
 1. Dactylitis[‡]  
 2. Nail pitting[§] and 
onycholysis 
 
 3. Psoriasis in a first-
degree relative 
 
Enthesitis-
related arthritis 
Arthritis and enthesitis,[||] 
or arthritis or enthesitis 
with at least 2 of the 
following:
A, D, E 
 1. Presence of or a history 
of sacroiliac joint 
tenderness or 
inflammatory lumbosacral 
pain or both[¶]
 
 2. Presence of HLA-B27 
antigen 
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Category Definition Exclusions 
 3. Onset of arthritis in a 
male >6 yr old
 
 4. Acute (symptomatic) 
anterior uveitis
 
 5. History of ankylosing 
spondylitis, enthesitis-
related arthritis, 
sacroiliitis with 
inflammatory bowel 
disease, Reiter's 
syndrome, or acute 
anterior uveitis in a first-
degree relative
 
Undifferentiated 
arthritis 
Arthritis that fulfills 
criteria in no category or 
in ≥2 of the above 
categories
 
RF, rheumatoid 
factor. 
  
∗ Quotidian fever is defined as a fever that rises to 39°C once 
a day and returns to 37°C between fever peaks. 
† Serositis refers to pericarditis, pleuritis, or peritonitis, or 
some combination of the three. 
‡ Dactylitis is swelling of ≥1 digits, usually in an asymmetric 
distribution, which extends beyond the joint margin. 
§ A minimum of 2 pits on any one or more nails at any time. 
|| Enthesitis is defined as tenderness at the insertion of a 
tendon, ligament, joint capsule, or fascia to bone. 
¶ Inflammatory lumbosacral pain refers to lumbosacral pain 
at rest with morning stiffness that improves on movement. 
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MASTER CHART 
S.N
o 
Name 
Age/ 
Sex 
Duratio
n of 
Illness 
Onset of 
Age 
Peripheral 
Joint 
Involvemen
t 
Axial 
Involvemen
t 
Enthesiti
s 
JADI
‐A 
JADI
‐E 
HAQ
‐S 
ESR 
CR
P 
HLA
‐ 
B27 
CT 
SI
J 
Develope
d AS 
1.   Murugan  15/
M 
3Month
s 
15  Yes  Yes  Yes  4  –  0.5‐
1.5 
62  >6  +    No 
2.   Sudhakar  12/
M 
1 Yr  11  Yes  No  Yes  4  –  –  0  –  –  N  – 
3.   Kaliyamoorthy  33/
M 
18 Yr  15  Yes  Yes  No  4  2  715  30  –  +    Yes 
4.   Srinivasan  16/
M 
6month
s 
15  Yes  Yes  Yes  8  –  0.5‐
1.5 
20  –  +    Yes 
5.   Balamurali  32/
M 
17yrs  15yr  No  Yes  No  –  –  71.5  28  –  –    Yes 
6.   Anilkumar  14/
M 
24Yrs  12 yrs  Yes  No  Yes  2  –  –  5  –  –  N  – 
7.   Anandh  23/
M 
9 yr  4 yr  Yes    No  2  –  –  26  >6  –  N  – 
8.   Lokesh  9/M  6month
s 
9  Yes  No  Yes  6  –  –  83  60  –  N  – 
9.   Dhanalakshmi  18/F  4yr  14  Yes  No  Yes  4  –  –  66  –  +  N  – 
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S.N
o 
Name 
Age/ 
Sex 
Duratio
n of 
Illness 
Onset of 
Age 
Peripheral 
Joint 
Involvemen
t 
Axial 
Involvemen
t 
Enthesiti
s 
JADI
‐A 
JADI
‐E 
HAQ
‐S 
ESR 
CR
P 
HLA
‐ 
B27 
CT 
SI
J 
Develope
d AS 
10.   Balakandan  26/
M 
12 yrs  14  Yes  Yes  Yes  10  –  71.5  88  6  –    Yes 
11.   Parveenkumar  24/
M 
5yrs  15yrs  Yes  Yes  Yes  10  –  –  120  –  –  N  – 
12.   Santhosh  16/
M 
2yr  14 yrs  Yes  No  Yes  2  –  –  10  –  –  N  – 
13.   Mani  13/
M 
6month
s 
14yrs        10  –  –  24  –  –  N  – 
14.   Kannadasan  20/
M 
6 Yrs  14yrs  Yes  Yes  Yes  10  –  0.5‐
1.5 
20  6  +    Yes 
15.   Balaji  31/
M 
23yrs  8yrs  Yes  Yes  Yes  12  –  0.5‐
1.5 
70  6  +    Yes 
16.   Sumanth  12/
M 
34yrs  9yrs  Yes  Yes  Yes  4  21  0.5‐
1.5 
40  –  –    Y 
17.   Vasu  13/
M 
5yrs  8yrs  Yes  No  Yes  4  –  –  25  –  –  –  – 
18.   Velmurugan  15/
M 
6month
s 
5yr  Yes  No  Yes  10  –  –  65  –  –  –  – 
19.   Saran  12/
M 
3month
s 
12  Yes  No  Yes  2  –  –  14  10  –  –  – 
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S.N
o 
Name 
Age/ 
Sex 
Duratio
n of 
Illness 
Onset of 
Age 
Peripheral 
Joint 
Involvemen
t 
Axial 
Involvemen
t 
Enthesiti
s 
JADI
‐A 
JADI
‐E 
HAQ
‐S 
ESR 
CR
P 
HLA
‐ 
B27 
CT 
SI
J 
Develope
d AS 
20.   Dakshanamoorth
y 
15/
M 
3month
s 
15month
s 
Yes  No  Yes  8  –  –  25  –  –  –  – 
21.   Rashak  15/
M 
4month
s 
15yrs  Yes  No  Yes  4  –  –  36  >6  +  –  – 
22.   Ghouse Basha  16/
M 
3yrs  13ys  Yes  No  Yes  4  –  –  31  –  +  –  – 
23.   Ramkumar  18/
M 
3yrs  15yrs  Yes  Yes  Yes  2  –  –  18  29  –     
24.   Kulasekaran  14yr
s 
3month
s 
14yrs  Yes  No  Yes  2  –  –  25  –  –  –  – 
25.   Sekaran  19/
M 
4yrs  15yrs  Yes  No  Yes  2  –  –  26  –  +    – 
26.   Veeramani  19/
M 
5yrs  14yrs  Yes  No  No  2  –  –  35  –  +    – 
27.   Krishnamoorthy  17/
M 
2yrs  15yrs  No  Yes  Yes  2  –  –  66  –  +    AS 
28.   Udayakumar  22/
M 
8yrs  14yrs  Yes  Yes  Yes  2  –  0.5  22  >6  –    AS 
29.   Rathnakumar  19/
M 
8yrs  11yrs  Yes  No  Yes  2  –  –  20  6  –  –  – 
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S.N
o 
Name 
Age/ 
Sex 
Duratio
n of 
Illness 
Onset of 
Age 
Peripheral 
Joint 
Involvemen
t 
Axial 
Involvemen
t 
Enthesiti
s 
JADI
‐A 
JADI
‐E 
HAQ
‐S 
ESR 
CR
P 
HLA
‐ 
B27 
CT 
SI
J 
Develope
d AS 
30.   Chandrasekaran  19/
M 
6yrs  13yrs  Yes  No  Yes  2  –  0.5‐
1.5 
70  >6  +    AS 
31.   Moideen  17/
M 
5yrs  12yrs  Yes  No  Yes  2  –  –  30  6  –    – 
32.   Elavarasan  16/
M 
24yrs  14yrs  Yes  No  Yes  4  –  –  26  6  –  –  – 
33.   Haribabu  23/
M 
10yrs  13yrs  Yes  No  Yes  2  –  –  15  –  +    Yes 
34.   Sylvester  16/
M 
34yrs  13yrs  Yes  Yes  Yes  2  –  0.5‐
1.5 
62  –  –  –  – 
35.   Shanmugam  16/
M 
2month
s 
14yrs  Yes  No  Yes  4  –  –  66  –  +    – 
36.   Adaikkalam  21/
M 
10yrs  11yrs  Yes  No  Yes  4  –  –  40  –  –    Yes 
37.   Dineshkumar  16/
M 
1yr  15yr  Yes  No  Yes  2  –  –  45  –  –    – 
38.   Selvapandian  14  3month  14month
s 
Yes  No  Yes  2  –  –  110  >6  –  –  – 
39.   Gopinath  17  9yrs  8yrs  Yes  No  Yes  2  –  –  17  6  –  –  – 
40.   Krishnamoorhty  17  24yrs  15yrs  Yes  Yes  Yes  4  –  –  36  6  –  –  – 
  83
S.N
o 
Name 
Age/ 
Sex 
Duratio
n of 
Illness 
Onset of 
Age 
Peripheral 
Joint 
Involvemen
t 
Axial 
Involvemen
t 
Enthesiti
s 
JADI
‐A 
JADI
‐E 
HAQ
‐S 
ESR 
CR
P 
HLA
‐ 
B27 
CT 
SI
J 
Develope
d AS 
41.   Vasanthakumar  17  2yrs  15yrs  Yes  Yes  Yes  6  –  –  70    –    – 
42.   Selvam  18/
M 
4yrs  14yrs  Yes  No  Yes  4  –  –  –  –  –  –  – 
43.   Ashok  18/
M 
4yrs  14yrs  Yes  Yes  Yes  4  –  –  12.
4 
–  –  –  – 
44.   Thangavelu  25/
M 
2yr  14yr  Yes  Yes  Yes  6  –  –  16  –  –  –  – 
45.   Chinappa  25/
M 
10yr  15yr  Yes  Yes  Yes  2  –  –  20  –  –    – 
46.   Kumaresan  13/
M 
6month
s 
13month
s 
Yes  No  Yes  1  –  –  100  –  –  –  – 
47.   Kunadharasan  14/
M 
6month
s 
13 yrs  Yes  No  Yes  2  –  –  40  –  –  –  – 
48.   Rasak  15/
M 
4month
s 
4montsh  Yes  No  Yes  4  –  –  36  6  +  –  – 
49.   Sarankumar  14/
M 
6month
s 
14yrs  Yes  No  Yes  2  –  –  30  6  +  –  – 
50.   Karthikeyan  13/
M 
2yrs  11yrs  Yes  No  Yes  2  –  –  10  –  +    Yes 
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Fig -1: X-Ray Shows Normal Sacroiliac Joint 
 
Fig-2: X-Ray Shows Bilateral Sacroilitis 
 85
 
Fig-3: CT Shows Left Side Sacroilitis 
 
Fig-4: MRI Shows Right Side Sacroilitis 
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Fig-5: Ultrasound shows knee enthesitis 
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Fig- 6: Ultrasound shows plantar fascitis 
 
Figure - 7: Ultrasound shows achillis enthesitis 
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ABBREVIATION 
JIA Juvenile idiopathic arthritis
RF Rheumatoid  factor
ERA Enthesitis related arthritis
AS Ankylosing spondylitis
SPA Spondyloarthropathy 
HLA Human leucocyte antigen
JADI Juvenile articular demage index
ESR Erythrocyte sedimentation rate
CRP C-Reactive protein
ANA Anti nuclear antibody
JAS Juvenile ankylosing spondylitis
TNF Tumor  necrosis factor 
NSAIDS Nonsteroidal anti-inflammatory drugs
HAQ-S Health assessment question-spine
DMARD Disease modifying anti rheumatic drugs
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CONSENT FORM 
STUDY TITLE     
A study on Outcome of Juvenile idiopathic arthritis –Enthesitis 
related arthritis 
Study Centre   : Department of Rheumatology, 
Madras Medical College, Chennai – 600 003 
 
Patient’s Name  : 
Patient’s Age   : 
Identification Number  :                
 Patient may check (3 ) these boxes 
 
I confirm that I have understood the purpose of procedure for the 
above study. I have the opportunity to ask the question and all my 
questions and doubts have been answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I 
am free to withdraw at any time without giving any reason, without 
my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethics committee and the regulatory authorities 
will not need my permission to look at my health records both in 
respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study. I agree 
to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any 
data or results that arise from this study. 
I agree to take part in the above study and to comply with the 
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instructions given during the study and to faithfully co-operate with 
the study team, and to immediately inform the study staff if I suffer 
from any deterioration in my health or well being or any unexpected 
or unusual symptoms. 
 
I hereby consent to participate in this study on ‘A study on outcome of 
Juvenile idiopathic arthritis –Enthesitis related arthritis. 
 
I hereby give permission to undergo complete clinical examination 
and diagnostic tests including hematological, biochemical, 
radiological and urine examination. 
 
Signature / Thumb Impression ___________________ Place _________ 
Date ____________ 
Patient’s Name and Address: __________________________________ 
Signature of the Investigator : ___________________ Place _________ 
Date ____________ 
Study Investigator’s Name : __________________________________ 
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PROFORMA 
STUDY ON OUTCOME OF JUVENILE IDIOPATHIC 
ARTHRITIS-ENTHESITIS RELATED ARTHRITIS 
Name   age   sex 
Address 
Duration 
Complaints 
Present  history 
Past  history 
Family  history 
Personal  history 
Treatment history 
General examination 
Conscious      febrile   PR        BP      
Lymphadenopathy      Jaundice 
Eye      Rash 
Systemic examination 
CVS      RS     ABD      CNS 
Musculoskeletal   examination 
Investigations 
Urine   routine                             Haemogram 
CRP                 LFT                RFT     
RF             ANA 
HLA B-27 
X-RAYS             
USG 
CT-SIJ 
Treatment 
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 97
Age Distribution (n=50)
2%
80%
11%
7%
<10 .10-20 20-30 >30
 
 
Peripheral Joint Involvement (n=50)
94%
6%
Yes No
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Axial Involvement (n=50)
64%
36%
Yes No
 
 
Enthesitis
70%
30%
Yes No
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2 2 3
7
35
0
5
10
15
20
25
30
35
<5 .5-10 .10-15 .15-20 >20
ESR Values
 
 
CRP Values
10
6
31
0
5
10
15
20
25
30
35
6 >6 Not Determined
 
 100
34%
66%
0%
10%
20%
30%
40%
50%
60%
70%
Positive Negative
HLA - B27
 
 
0
1
2
3
4
5
6
7
0.5 0.5  ‐ 1.5 1.5
1
7
3
HAQ‐S
N=50
 
